MUNICH, Sept. 20, 2011 /PRNewswire/ -- Definiens, the leading Health Image Intelligence™ company, announces that it will release a new generation of products at the International Definiens Symposium at the Moffitt Cancer Center in Tampa, FL on October 17–18. The annual symposium is the premier forum for Definiens users and developers from around the world to present the latest applications, research and workflows in life science image and data analysis. One focus of this year's symposium will be tissue-based biomarker research and image analysis in clinical trials. The high-caliber program will include a speaker panel with key opinion leaders from industry and academia.
Definiens Tissue Studio® software has already been established as an industry standard. Building on the company's vast background in biomedical image analysis and biomarker research, existing products for image analysis, such as Tissue Studio, will be significantly improved, with a focus on Quantitative Digital Pathology. In addition, a completely new component will be added to Definiens' suite of products, which will allow users to leverage the enormous value of received measurements and data. This component will closely integrate image analysis with data and image mining.
The technology will provide high accuracy in automatically identifying relevant structures of interest and specific morphology in histology, resulting in a detailed phenotypic fingerprint and biomarker expression profile on a cell-by-cell basis. The large set of descriptors can be correlated against therapy response or patient outcome with the goal to identify new types of biomarkers of predictive or prognostic value.
"It is clear that today only a small portion of the information contained in tissue biopsies is used for research or diagnosis and the interpretation is subjective," says Thomas Heydler, CEO of Definiens. "With the statistical power of many detailed readouts from a tumor specimen combined with our new data mining capabilities, we are addressing the needs of scientists and exploring new possibilities in tissue-based biomarker development."
In recent years, Definiens has generated a large footprint over the entire bandwidth of biomedical applications, specifically in the field of Quantitative Digital Pathology and Biomarker Research, which continues to expand with the upcoming additions to the company's suite of products. For more information about the upcoming product launch, please visit quantitative-digital-pathology.definiens.com.
For more information on the upcoming International Definiens Symposium, please visit www.definiens.com/community/symposium.html.
Definiens is a leading Health Image Intelligence™ company that develops software solutions for biomedical image analysis, data mining and clinical decision support. The company's software analyzes images from cell-based assays, whole tissue slides and full body scans and allows users to correlate this information with data derived from other sources, supporting better decisions in research, diagnostics and therapy. By automating analysis workflows and generating new knowledge, Definiens provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and medical professionals with deeper insights, faster results and better decision support. Harnessing the power of image intelligence, Definiens supports personalized medicine and aims to significantly improve the quality of patients' lives.
Definiens is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at www.definiens.com.
Dr. Martin Baatz
Vice President Marketing
212.679.3300 ext. 120